Histone Deacetylase Inhibition Decreases Cholesterol Levels in Neuronal Cells by Modulating Key Genes in Cholesterol Synthesis, Uptake and Efflux

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Nunes, Maria João ^a   Moutinho, Miguel ^a   Gama, Maria João ^a   Rodrigues, Cecília M P ^a   Rodrigues, Elsa ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HISTONE DEACETYLASE; TRICHOSTATIN A;

ARTICLE; BIOACCUMULATION; CELL LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NERVE CELL; REGULATOR GENE; UPREGULATION;

ANDROSTENES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLESTEROL; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SPACE; LYSOSOMES; NEURONS; PHENOTYPE; PROTEOLYSIS; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION, GENETIC;

EID: 84872249052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053394     Document Type: Article

References (48)

1. Dietschy JM, Turley SD, (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45: 1375-1397.
2. Strittmatter WJ, Roses AD, (1996) Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 19: 53-77.
3. Rosenbaum AI, Maxfield FR, (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem 116: 789-795.
4. Vetrivel KS, Thinakaran G, (2010) Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 1801: 860-867.
5. Zlokovic BV, (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
6. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, et al. (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93: 9799-9804.
7. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, et al. (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39: 1594-1600.
8. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM, (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 44: 1780-1789.
9. Lund EG, Guileyardo JM, Russell DW, (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 96: 7238-7243.
10. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, et al. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278: 22980-22988.
11. Shafaati M, Olin M, Bavner A, Pettersson H, Rozell B, et al. (2011) Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. J Intern Med 270: 377-387.
12. Ohyama Y, Meaney S, Heverin M, Ekstrom L, Brafman A, et al. (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 281: 3810-3820.
13. Milagre I, Nunes MJ, Gama MJ, Silva RF, Pascussi JM, et al. (2008) Transcriptional regulation of the human CYP46A1 brain-specific expression by Sp transcription factors. J Neurochem 106: 835-849.
14. Milagre I, Nunes MJ, Castro-Caldas M, Moutinho M, Gama MJ, et al. (2012) Neuronal differentiation alters the ratio of Sp transcription factors recruited to the CYP46A1 promoter. J Neurochem 120: 220-229.
15. Milagre I, Olin M, Nunes MJ, Moutinho M, Lovgren-Sandblom A, et al. (2012) Marked change in the balance between CYP27A1 and CYP46A1 mediated elimination of cholesterol during differentiation of human neuronal cells. Neurochemistry international 60: 192-198.
16. Milagre I, Nunes MJ, Moutinho M, Rivera I, Fuso A, et al. (2010) Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination. Journal of Alzheimer's disease: JAD 22: 1209-1221.
17. Nunes MJ, Milagre I, Schnekenburger M, Gama MJ, Diederich M, et al. (2010) Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J Neurochem 113: 418-431.
18. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23: 9418-9427.
19. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100: 2041-2046.
20. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280: 556-563.
21. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98: 9808-9813.
22. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, et al. (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. The Journal of clinical investigation 117: 659-671.
23. Corcoran LJ, Mitchison TJ, Liu Q, (2004) A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Current biology: CB 14: 488-492.
24. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087-1098.
25. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40-49.
26. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of neuroimmunology 164: 10-21.
27. Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, et al. (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 108: 5620-5625.
28. Cenedella RJ, (2009) Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44: 477-487.
29. Castro-Caldas M, Milagre I, Rodrigues E, Gama MJ, (2009) Glutathione S-transferase pi regulates UV-induced JNK signaling in SH-SY5Y neuroblastoma cells. Neurosci Lett 451: 241-245.
30. Sato R, (2010) Sterol metabolism and SREBP activation. Arch Biochem Biophys 501: 177-181.
31. Horton JD, Goldstein JL, Brown MS, (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. The Journal of clinical investigation 109: 1125-1131.
32. Subramanian C, Jarzembowski JA, Opipari AW Jr, Castle VP, Kwok RP, (2007) CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia 9: 495-503.
33. Kim SJ, Lee BH, Lee YS, Kang KS, (2007) Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem Biophys Res Commun 360: 593-599.
34. Villagra A, Ulloa N, Zhang X, Yuan Z, Sotomayor E, et al. (2007) Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J Biol Chem 282: 35457-35470.
35. Xu Y, Bao Y, Hong B, Si S, (2011) Identification of dehydroxytrichostatin A as a novel up-regulator of the ATP-binding cassette transporter A1 (ABCA1). Molecules 16: 7183-7198.
36. Munkacsi AB, Chen FW, Brinkman MA, Higaki K, Gutierrez GD, et al. (2011) An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. J Biol Chem 286: 23842-23851.
37. Haggarty SJ, Tsai LH, (2011) Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiology of learning and memory 96: 41-52.
38. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT, (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
39. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, et al. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
40. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, et al. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357.
41. Goritz C, Mauch DH, Pfrieger FW, (2005) Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 29: 190-201.
42. Fan QW, Yu W, Gong JS, Zou K, Sawamura N, et al. (2002) Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem 80: 178-190.
43. Pentchev PG, Comly ME, Kruth HS, Vanier MT, Wenger DA, et al. (1985) A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc Natl Acad Sci U S A 82: 8247-8251.
44. Liscum L, Faust JR, (1987) Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts. J Biol Chem 262: 17002-17008.
45. Xie C, Turley SD, Dietschy JM, (1999) Cholesterol accumulation in tissues of the Niemann-pick type C mouse is determined by the rate of lipoprotein-cholesterol uptake through the coated-pit pathway in each organ. Proc Natl Acad Sci U S A 96: 11992-11997.
46. Pfrieger FW, (2003) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-78.
47. Zhang M, Strnatka D, Donohue C, Hallows JL, Vincent I, et al. (2008) Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc1-/- mice. J Neurosci Res 86: 2848-2856.
48. Goldstein JL, DeBose-Boyd RA, Brown MS, (2006) Protein sensors for membrane sterols. Cell 124: 35-46.